The research, led by Federica Banche-Niclot, Rosalia Ferraro, Francesca Taraballi, and Sergio Caserta across institutions in the United States and Italy, addresses a persistent gap in translational cancer research. Mechanical alterations within the tumor microenvironment, including stiffening of the extracellular matrix, altered tissue viscoelasticity, and increased cellular deformability, are not passive byproducts of disease. Instead, these biomechanical cues actively reshape cellular behavior, influencing how cancer cells invade, migrate, survive under stress, and respond to chemotherapy. Yet despite this recognized importance, mechanical phenotype remains underutilized in diagnostic and therapeutic workflows, and few platforms exist that allow controlled, quantitative exploration of these mechanical dynamics.

Conventional tools for studying tissue mechanics have significant limitations. Atomic force microscopy, indentation, micro tweezers, and compression assays have all contributed valuable insights into cellular elasticity, but they often oversimplify the inherently viscoelastic nature of biological systems. These techniques are sensitive to tool geometry and substrate properties, producing high variability and limited comparability, especially when moving from isolated cells to tissue-level constructs. The new study instead places rotational rheology at the center of its strategy. By measuring the elastic storage modulus G-prime and the viscous loss modulus G-double-prime, rheology captures both energy storage and dissipation, the key parameters governing how tumors deform, resist, or transmit mechanical stress. These moduli can be converted into conventional metrics such as Young’s modulus under defined assumptions, enabling comparisons across biological models.

To build a physiologically relevant in vitro system, the team cultured two distinct cell lines as three-dimensional spheroids using the liquid overlay technique. Cancer spheroids were formed from MDA-MB-231 human breast adenocarcinoma cells, a line derived from a patient with metastatic disease, while non-tumoral spheroids were formed from primary human mesenchymal stem cells isolated from infrapatellar fat pad tissue under institutionally approved protocols. Spheroids were grown in U-bottom 96-well plates coated with a nonstick polyHEMA film, which promotes cell-to-cell aggregation. Viability was tracked over 72 hours using an ATP-based metabolic assay alongside live/dead fluorescent staining. The mesenchymal spheroids developed a necrotic core by 72 hours, so they were mechanically tested at 24 hours, whereas the cancer spheroids reached a compact, nearly spherical morphology with sustained viability at 72 hours and were tested at that timepoint.

A critical design challenge was how to hold the spheroids in place during rheological measurement without contaminating the mechanical signal. The researchers embedded the spheroids in a purified methacrylated Type I bovine collagen hydrogel at 3 milligrams per milliliter, cast into disks matching the 25-millimeter rheometer plate. Spheroid numbers were calculated to achieve roughly 1 percent surface coverage of the supporting disk, requiring 15 cancer spheroids or 85 mesenchymal spheroids per sample. The bare collagen gel proved to be approximately three orders of magnitude softer than the spheroid-laden constructs, with a storage modulus of only about 78 pascals at an angular frequency near 1 radian per second, confirming that the support matrix did not mask the mechanics of the cells themselves.

The rheological results revealed a striking mechanical contrast. At an angular frequency of about 1 radian per second, the storage modulus reached 9.70 plus or minus 1.83 times 10 to the fourth pascals for constructs containing healthy spheroids and 2.45 plus or minus 1.13 times 10 to the fifth pascals for those containing cancer spheroids, a 2.5-fold difference in stiffness. The loss tangent, the ratio of viscous to elastic response, stayed nearly constant at around 0.30 for healthy constructs and 0.15 for tumoral ones, indicating that the cancer spheroids behaved in an even more solid-like fashion. Converting the storage moduli into Young’s modulus values assuming incompressible behavior yielded approximately 2.91 times 10 to the fifth pascals for healthy constructs and 7.36 times 10 to the fifth pascals for tumoral constructs. This stiffening is consistent with the extracellular matrix remodeling, increased collagen crosslinking, and heightened contractile forces that characterize aggressive cancer phenotypes and promote migration and invasion.

To validate the in vitro platform against real biology, the team benchmarked it with ex vivo tissues: healthy mammary gland fat pads from mice and tumor masses generated by injecting MDA-MB-231 cells into mice. Tissues were rehydrated in phosphate-buffered saline and standardized to 5-millimeter cylinders with a biopsy punch. Rheological testing showed the same directional pattern as the spheroid models, with tumoral tissues approximately ten times stiffer than healthy counterparts, exhibiting storage moduli of 2.38 plus or minus 1.04 times 10 to the fifth pascals versus 2.45 plus or minus 0.93 times 10 to the fourth pascals. Both tissue types displayed solid-like behavior, with the storage modulus consistently exceeding the loss modulus across the tested frequency range of 0.01 to 100 radians per second.

One of the study’s most technically important findings emerged from comparing rheology with compression testing. Compression measurements using a Hertz model analysis of the stress-strain curve, restricted to strains below 10 percent to remain in the linear elastic regime, gave Young’s modulus values of 3.68 plus or minus 0.38 times 10 to the fourth pascals for healthy tissue and 5.22 plus or minus 0.62 times 10 to the fourth pascals for tumoral tissue, making tumors about 1.42 times stiffer. These absolute values differed from the rheological estimates, but the discrepancy was resolved when the applied normal force was taken into account. Healthy tissues exhibited force-softening, with moduli decreasing by at least an order of magnitude as normal force increased, while tumoral tissues showed force-stiffening, with moduli rising under higher load. When rheological values were compared within the same normal force window reached during compression, roughly 0.1 to 0.15 newtons, the two methods agreed closely. The authors emphasize that this nonlinear, force-dependent behavior can introduce serious artifacts into biomechanical characterization if not standardized, and that mechanical comparisons must be made within consistent force regimes.

The translational implications are considerable. Increased tumor stiffness is known to hinder drug diffusion, impair immune cell infiltration, and activate mechanotransduction pathways that promote chemoresistance. By reproducing this stiffness landscape in vitro and aligning it with ex vivo profiles, the platform enables a more predictive evaluation of mechanically responsive therapies before animal or clinical testing. The authors also point toward mechanical fingerprinting as a potential physical biomarker strategy, particularly if integrated with imaging techniques or functional assays. The standardized hydrogel scaffolds, controlled spheroid assembly, and quantitative mechanical outputs make the approach suitable not only for academic investigation but also for industrial drug screening and biomaterials testing pipelines.

The researchers are careful to note the limitations and the road ahead. Bulk rheological metrics provide standardization and throughput, but they cannot fully describe the mechanical microenvironment experienced by individual cells, which varies spatially due to heterogeneity in matrix density and local architecture. Cell-scale techniques such as atomic force microscopy and microrheology capture local stiffness gradients relevant to mechanotransduction but require careful model assumptions and are sensitive to sampling location, so bulk and microscale measurements should be treated as complementary rather than competing descriptors. Future work will expand the platform to larger ex vivo cohorts, incorporate additional cell populations and tumor subtypes, add dynamic cues such as perfusion and immune components, and account for sex as a biological variable, since hormone-dependent signaling can modulate stromal behavior and matrix remodeling. Mycoplasma testing was not performed in this proof-of-concept study, though no morphological abnormalities or altered growth kinetics were observed. Even so, the framework establishes a reproducible mechanical benchmark for breast cancer, laying the groundwork for embedding biomechanical profiling into preclinical workflows, mechanics-informed diagnostics, and patient-specific modeling.

Subject of Research: Viscoelastic biomechanical profiling of healthy and cancerous breast tissue using 3D spheroid models and ex vivo rheology

Article Title: Mechanical fingerprints in breast cancer research: A multimodal experimental approach

Article References: Banche‐Niclot, F., Ferraro, R., Di Palo, V., de Paolis, P., Taraballi, F., & Caserta, S. (2026). Mechanical fingerprints in breast cancer research: A multimodal experimental approach. Bioengineering & Translational Medicine, 11(5), Article e70148. https://doi.org/10.1002/btm2.70148

Image Credits: AI Generated

DOI: 10.1002/btm2.70148

Keywords: breast cancer, tumor biomechanics, rheology, 3D spheroids, viscoelasticity, extracellular matrix, tumor stiffness, Young's modulus, compression testing, drug delivery, mechanotransduction, ex vivo tissue analysis

The review begins by cataloguing the mechanical abnormalities that define the solid tumor microenvironment. Desmoplastic tumors, such as pancreatic ductal adenocarcinoma, deposit dense stromal matrix rich in collagen, crosslinked in part by enzymes like lysyl oxidase, producing tissue that can be far stiffer than healthy surrounding tissue. Growing cell masses generate solid stress that compresses blood and lymphatic vessels, raising interstitial fluid pressure and distorting fluid flow. Cancer-associated fibroblasts amplify this stiffness by contracting the matrix and depositing new extracellular material. These physical cues are not passive background conditions; cells sense them through integrin-based adhesions, mechanosensitive ion channels, and cytoskeletal networks, converting mechanical information into biochemical signals that reach all the way into the nucleus and alter gene expression.

The canonical mechanotransduction pathways described in the review provide plausible routes by which physical forces could reach the RNA modification machinery. Integrin-focal adhesion kinase signaling couples matrix rigidity to downstream cascades including PI3K-AKT, MAPK, and Rho-associated kinase pathways. The transcriptional coactivators YAP and TAZ, which respond to substrate stiffness and cytoskeletal tension, shuttle into the nucleus under mechanical loading and reprogram transcription. The stretch-activated ion channel PIEZO1 converts membrane tension into calcium influx, triggering downstream signaling. Cytoskeletal remodeling and nuclear deformation, mediated in part by LINC complexes that physically connect the cytoskeleton to the nuclear interior, can even alter chromatin organization directly. Each of these conduits, the authors argue, represents a potential input channel to the enzymes that write, erase, and read chemical marks on RNA.

Those enzymes are the heart of the epitranscriptome. N6-methyladenosine, or m6A, is the most abundant internal modification of messenger RNA and is installed by writer complexes containing METTL3, METTL14, and WTAP, removed by erasers such as FTO and ALKBH5, and interpreted by readers including YTHDF proteins and IGF2BP family members. Other modifications, including 5-methylcytosine, 7-methylguanosine, and pseudouridine, together with adenosine-to-inosine RNA editing, further diversify the informational content of the transcriptome. The review emphasizes that the activity, localization, and expression of these writers, erasers, and readers could plausibly be modulated by mechanical signaling. For example, YAP/TAZ-driven transcriptional programs could alter the expression levels of modification enzymes, while calcium influx through PIEZO1 could regulate enzymatic activity through calcium-dependent signaling, and nuclear deformation could influence where modification enzymes reside within the cell.

The most striking aspect of the review is its intellectual honesty about the state of the evidence. The authors applied a tiered classification to the studies they surveyed and found that only two investigations meet the strictest Tier-1 definition of mechanosensitive epitranscriptomics in cancer-relevant systems. The first is a study in pancreatic ductal adenocarcinoma showing that substrate stiffness influences the METTL14 and IGF2BP3 axis in a YAP1-dependent manner, linking matrix rigidity to m6A deposition and downstream oncogenic outputs. The second demonstrates that mechanical stiffness regulates the m6A eraser FTO in macrophages, thereby controlling Socs1 expression and shaping macrophage polarization, a process central to tumor immune dynamics. Most other reported connections between mechanics and RNA modification, the authors caution, remain Tier-3 hypotheses or associations potentially confounded by parallel changes in oxygen tension, inflammation, or metabolism that accompany altered mechanical environments.

Distinguishing direct mechanoregulation from these secondary effects is a central challenge the review confronts head-on. A stiff, hypoperfused tumor region is simultaneously stiff, hypoxic, nutrient-deprived, and inflamed. Hypoxia-inducible factors can independently regulate RNA modification enzymes, and inflammatory cytokines such as transforming growth factor beta do the same. To untangle this web, the authors propose testable experimental models: decoupling stiffness from hypoxia using engineered matrices, applying controlled mechanical stretch to cells in isolation, and using temporally precise perturbations to determine whether mechanical inputs causally drive changes in RNA modification rather than merely correlating with them. Such designs, they argue, are essential before the field can claim that mechanics acts directly on the epitranscriptomic machinery rather than through intermediary stress responses.

The tumor-immune interface is where the stakes of this framework become highest. Mechanical stress and RNA modifications jointly influence nearly every process that determines whether a tumor is recognized and destroyed by the immune system. Antigen presentation depends on the translation and processing of major histocompatibility complex components, processes that m6A and other modifications can tune. Interferon signaling, which alert neighboring cells to the presence of tumor antigens, is sensitive to RNA editing levels, since adenosine-to-inosine editing can alter how double-stranded RNA is perceived by innate immune sensors. Checkpoint molecules such as PD-L1 are themselves subject to RNA modification control. The review details how these regulatory layers could affect T-cell and natural killer cell function, the polarization of myeloid cells toward immunosuppressive fates, and the physical exclusion of immune cells from tumor nests, where stromal stiffness forms a mechanical barrier to immune infiltration.

On the translational side, the review outlines strategies for converting this framework into clinical tools. Magnetic resonance elastography already allows noninvasive mapping of tissue stiffness in patients, and combining such mechanical imaging with single-cell epitranscriptomic profiling, using methods like single-cell RNA sequencing, methylated RNA immunoprecipitation sequencing, and deamination-based modification mapping, could reveal how mechanical niches within tumors correspond to distinct RNA modification states. The authors envision composite biomarkers that integrate tumor mechanics, epitranscriptomic signatures, and predicted immunotherapy response, potentially identifying patients likely to benefit from immune checkpoint blockade. They also suggest that enzymes such as FTO, METTL14, or METTL3 could themselves become therapeutic targets, either alone or in combination with mechanical normalization strategies such as drugs that reduce matrix stiffness or stromal pressure, thereby softening the tumor microenvironment while simultaneously reprogramming RNA regulation.

What makes this review compelling is its refusal to overstate a young field. By explicitly ranking the evidence and naming the two Tier-1 studies, the authors provide a benchmark against which future work can be measured, and they openly acknowledge that much of the mechanosensitive epitranscriptomic landscape in cancer remains hypothetical. Yet the framework they assemble is rich with testable predictions: that specific mechanotransduction channels converge on specific modification enzymes, that these enzymes modify specific transcript subsets governing immune recognition, and that disrupting these circuits could restore immune visibility to mechanically armored tumors. As sequencing technologies for RNA modifications grow faster and more precise, and as engineered matrices allow cleaner mechanical experiments, the coming years should reveal whether the convergence of tumor mechanics and RNA chemistry is a genuine biological axis or a seductive correlation. Either way, the review establishes a clear roadmap for finding out, and in doing so adds a provocative new dimension to the ongoing effort to understand why some tumors so successfully hide from the immune system.

Subject of Research: How tumor mechanics regulate RNA modifications and immune escape in cancer

Article Title: Mechanosensitive epitranscriptomics in cancer: linking tumor mechanics, RNA modification, and immune escape

Article References: Jiang, M., Zhang, K., Li, M., Yao, J., Shi, R., Sun, C., Rodríguez, R. A., Lin, Z., Meng, J., Wang, Z., Wu, S., Luo, M., Zhang, W., Wei, R., Bai, Y., Lai, G., Zhang, C., Bo, Z., & Wang, T. (2026). Mechanosensitive epitranscriptomics in cancer: linking tumor mechanics, RNA modification, and immune escape. Molecular Cancer. https://doi.org/10.1186/s12943-026-02784-6

Image Credits: AI Generated

DOI: 10.1186/s12943-026-02784-6

Keywords: mechanosensitive epitranscriptomics, RNA modifications, m6A, mechanotransduction, tumor microenvironment, immune escape, cancer immunotherapy, YAP/TAZ, METTL14, FTO, tumor stiffness, Molecular Cancer